Browse Discover Builder Rankings Pricing

Private market intelligence for investors, founders, and sales teams.

Product

Browse
Discover
List Builder
Rankings
Pricing

Developers

API Reference
API Keys

Company

About
Terms
Privacy
Contact

© 2026 Indexed.vc. All rights reserved.

Protalix BioTherapeutics, Inc. (DE): Company Profile & Funding | Indexed.vc

Protalix BioTherapeutics, Inc. (DE)

IPO

Protalix.com

Headquarters: Carmiel
Employees: 51–200
Founded: 1993
Business Model: B2B
Website: protalix.com

Total Funding: $52.6M
Last Round: $43.7M Growth EquityMar 2020
Rounds: 3
Type: Public

About

Biopharmaceutical company developing recombinant therapeutic proteins using proprietary plant cell-based expression system for rare diseases.

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Growth EquityGrowth EquityMar 2020

Mar 2020

IPOJan 2006

Jan 2006

Venture UnknownVenture RoundDec 2005

Dec 2005

Venture UnknownVenture RoundJan 2005

Jan 2005

Investors

Sign up to view investors

Create a free account to see which investors have funded this company.

Create Free Account

Similar Companies

BridgeBio PharmaIPO

BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...

Palo Alto, United States501–1000healthtech, biotech

Growth Equity·$1.2B·Jan 2024

Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...

New York, United States51–200healthtech, biotech

Angel·$585.0M·Oct 2019

ADC Therapeutics SA Common SharesIPO

Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.

Lausanne, Switzerland201–500healthtech, biotech

Series E·$501.0M·Jun 2019

Biohaven Ltd. Common SharesIPO

Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...

New Haven, United States201–500healthtech, biotech

Venture Unknown·$493.6M·Aug 2020

Nektar TherapeuticsIPO

Research-based development stage biopharmaceutical company that discovers and develops innovative...

San Francisco, United States51–200biotech, immunotherapy

Corporate Round·$460.0M·Feb 2026

Immatics N.V.IPO

Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...

Tuebingen, Germany201–500healthtech, biotech

Corporate Round·$346.7M·Dec 2025